Xilio Therapeutics, Inc. XLO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 327.25% | 476.71% | 589.88% | 588.40% | 536.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 327.25% | 476.71% | 589.88% | 588.40% | 536.44% |
| Cost of Revenue | 445.20% | 641.99% | 100.00% | -74.78% | -82.35% |
| Gross Profit | 309.32% | 267.44% | 161.38% | 251.32% | 246.98% |
| SG&A Expenses | 0.59% | 3.56% | 19.90% | 16.92% | 15.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.23% | 44.54% | 29.94% | 9.91% | 3.75% |
| Operating Income | 44.63% | 25.83% | 29.61% | 31.76% | 15.07% |
| Income Before Tax | 61.17% | 42.36% | 39.84% | 6.87% | 14.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 61.17% | 42.36% | 39.84% | 6.87% | 14.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.17% | 42.36% | 39.84% | 6.87% | 14.21% |
| EBIT | 44.63% | 25.83% | 29.61% | 31.76% | 15.07% |
| EBITDA | 45.41% | 26.07% | 30.28% | 32.43% | 15.24% |
| EPS Basic | 62.74% | 37.42% | 53.25% | 44.28% | 58.46% |
| Normalized Basic EPS | 62.77% | 37.42% | 52.05% | 43.21% | 57.75% |
| EPS Diluted | 62.74% | 37.42% | 53.25% | 44.28% | 58.46% |
| Normalized Diluted EPS | 62.77% | 37.42% | 52.05% | 43.21% | 57.75% |
| Average Basic Shares Outstanding | 13.22% | 0.51% | 20.89% | 49.20% | 100.61% |
| Average Diluted Shares Outstanding | 13.22% | 0.51% | 20.89% | 49.20% | 100.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |